2211-27-0

Basic information

• Product Name: Menadiol monoacetate
• Synonyms: Menadiol monoacetate;(4-hydroxy-2-methyl-1-naphthyl) acetate;(4-hydroxy-2-methylnaphthalen-1-yl) acetate;(4-hydroxy-2-methyl-naphthalen-1-yl) ethanoate;4-hydroxy-2-methyl-1-naphthyl acetate;acetic acid (4-hydroxy-2-methyl-1-naphthyl) ester;Naphthalene-1,4-diol, 1-O-acetyl-2-methyl-
• CAS NO: 2211-27-0
• Molecular Formula: C₁₃H₁₂O₃
• Molecular Weight: 216.235
• Mol File: 2211-27-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 124.5-125.8 °C
• Boiling Point: 385.8 °C at 760 mmHg
• Flash Point: 168.4 °C
• Appearance: /
• Density: 1.229 g/cm³
• Vapor Pressure: 1.67E-06mmHg at 25°C
• Refractive Index: 1.624
• PKA: 9.30±0.40(Predicted)
• CAS DataBase Reference: Menadiol monoacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Menadiol monoacetate(2211-27-0)
• EPA Substance Registry System: Menadiol monoacetate(2211-27-0)

Safety Data

• Hazardous Substances Data: 2211-27-0(Hazardous Substances Data)

Usage

General Description

Menadiol monoacetate, also known as vitamin K3 acetate, is a synthetic form of vitamin K. It is commonly used as a nutritional supplement to help with blood clotting and bone health. Menadiol monoacetate is fat-soluble and is involved in the process of blood coagulation, as well as maintaining bone health and regulating calcium levels in the body. It is often added to animal feed to prevent vitamin K deficiency and can also be used in baby formula and other food products for human consumption. However, its use as a nutritional supplement in humans is limited due to potential toxicity and the availability of other safer forms of vitamin K. Despite its limitations, menadiol monoacetate continues to be studied for its potential health benefits and uses in various applications.

InChI:InChI=1/C13H12O3/c1-8-7-12(15)10-5-3-4-6-11(10)13(8)16-9(2)14/h3-7,15H,1-2H3

Upstream product

• 573-20-6 menadiol di(acetate) 
• 67-56-1 methanol 
• 7664-41-7 ammonia 
• 58-27-5 menadione 
• 481-85-6 2-methyl-1,4-naphthohydroquinone 

Downstream Products

• 125544-58-3 4-Acetoxy-3-methyl-2-(1-phenyl-propyl)-[1]naphthol 
• 84-80-0 phytomenadione 
• 50281-47-5 4-Hydroxy-2-methyl-3-<(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl>naphth-1-yl Acetate 
• 34185-71-2 3-(5-carboxy-3-methyl-(2E)-penten-1-yl)-2-methyl-1,4-naphthoquinone 
• 53772-22-8 4-Benzyloxy-1-methoxy-2-methyl-naphthalene 
• 53772-21-7 2-methyl-4-benzyloxy-1-naphthol 
• 102749-26-8 1,4-diacetoxy-2-methyl-3-(1-phenyl-propyl)-naphthalene 
• 916432-92-3 1-(1-benzyloxy-3-methylnaphthalen-4-yloxy)propan-2-one 
• 4197-92-6 (2RS)-6-acetoxy-2,5-dimethyl-2-(4,8,12-trimethyl-decan-1-yl)-3,4-dihydro-2H-naphtho[1,2-b]pyran 
• 53772-20-6 1-benzyloxy-3-methylnaphthalen-4-yl acetate 

Relevant articles and documents

Method for the determination of vitamin K homologues in human plasma using high-performance liquid chromatography-tandem mass spectrometry

We report here the development of a precise and sensitive method for the determination of vitamin K homologues including phylloquinone (PK), menaquinone-4 (MK-4), and menaquinone-7 (MK-7) in human plasma using HPLC-tandem mass-mass spectrometry with atmospheric pressure chemical ionization (LC-APCI-MS/MS). The method involves the use of stable isotope 18O-labeled internal standard compounds, which were synthesized in our laboratory, and the selection of a precursor and product ion with a MS/MS multiple reaction monitoring method. The average intraassay and interassay variation values for PK, MK-4, and MK-7 were 10%. Average spiked recoveries from authentic compounds added to normal human plasma samples for PK, MK-4, and MK-7 were 98-102%. Mean plasma concentrations of PK, MK-4, and MK-7 from healthy subjects (n = 20) were 1.22 ± 0.57, 0.39 ± 0.46, and 6.37 ± 7.45 ng/mL, respectively. We conclude that this novel LC-APCI-MS/MS method should be useful for the evaluation of vitamin K status in postmenopausal women and elderly subjects and provides useful information for the treatment and prevention of osteoporosis with vitamin K.

Functional investigation and applications of the acetylesterase activity of the Citrus sinensis (L.) Osbeck peel

The hydrolysis of acetyl moieties on a set of commercially relevant substrates was performed by employing the whole tissue of Citrus sinensis (L.) Osbeck peel as an efficient biocatalyst in mild reaction conditions with high degree of regioselectivity. The reaction is done in aqueous media and the product is easily recovered. Optimal reaction conditions were deduced and two practical applications were investigated: the elaboration of acetylglicerols and the preparation of vitamin K1 precursor. Peel waste (flavedo and albedo) from orange juice manufacturing was successfully employed as a biocatalyst.

A METHOD OF MAKING VITAMIN K1

This invention discloses a method of making vitamin K1. The mentioned method of making vitamin K1 comprises performing a first one-pot synthesis with base catalyst, performing a first hydrolysis, performing a substitution, and performing a second one-pot synthesis for oxidation reaction without using metal oxidant. The starting material of this invention is stable 2-methyl-1,4-naphthoquinone. Preferably, this invention provides a method of making vitamin K1 efficiently on simplifying the operation and decreasing the formation of side-product. More preferably, without the usage of metal residue in this invention results that the vitamin K1 is more safety for clinical application.